Market Overview

Cramer Recommends J&J For Best Big Pharma Pipeline Play

Share:
Related JNJ
Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers
Technician Breaks Down Johnson & Johnson
Gilead's Brilliant Hepatitis C Strategy (Seeking Alpha)

Coming out of the Twittersphere Wednesday afternoon: a trader asks Jim Cramer about a potential big pharma play which could fit into his or her portfolio. The trader specified the play would need to be for over the next five years. Cramer responded:

J&J (NYSE: JNJ) shares do not seem to be responding to the recommendation by Cramer, but are trading at afternoon highs. The stock is down 0.6 percent to $92.74 at last check.

Posted-In: News Jim Cramer Media Trading Ideas

 

Related Articles (JNJ)

Around the Web, We're Loving...